Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $29.67

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $29.6667.

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Upstream Bio in a report on Wednesday, September 2nd. Truist Financial lowered their target price on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Finally, Wall Street Zen lowered Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio bought a new position in shares of Upstream Bio during the second quarter valued at $33,000. Persistent Asset Partners Ltd acquired a new stake in shares of Upstream Bio in the 2nd quarter valued at $34,000. Hsbc Holdings PLC acquired a new position in shares of Upstream Bio during the second quarter valued at $78,000. Canada Pension Plan Investment Board bought a new position in shares of Upstream Bio in the 2nd quarter valued at about $80,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Upstream Bio in the 2nd quarter valued at $86,000.

Upstream Bio Trading Down 5.5%

Upstream Bio stock opened at $5.19 on Friday. Upstream Bio has a 52 week low of $4.99 and a 52 week high of $33.68. The stock has a market cap of $284.26 million, a price-to-earnings ratio of -1.79 and a beta of 1.28. The company’s 50-day moving average price is $6.47 and its two-hundred day moving average price is $7.68.

Upstream Bio (NASDAQ:UPB) last released its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The firm had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. Research analysts expect that Upstream Bio will post -2.84 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company’s research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies.

Upstream Bio’s lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses.